Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. - Wikidata - wikimedia - TriplyDB

Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

http://www.wikidata.org/entity/Q33631435

about

Advances in the management of paediatric high-grade glioma.Profile of nimotuzumab in the treatment of high-grade glioma Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Glioblastoma antigen discovery--foundations for immunotherapy.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.Trends in Malignant Glioma Monoclonal Antibody Therapy.Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan.

P2860

Q30870633-294D3BEB-0B4C-4CF9-A23D-9D2BF9963331 Q35491503-3AF55C1E-8C67-4625-9260-ABE8D67178BC Q37269328-187D0CF0-FADC-46A7-9F09-44FE267B4E88 Q38214511-342218CD-38A7-4E69-8857-A5FF2C5F6216 Q38516823-4B6CABC7-D0E7-4FE3-830B-2CF8A60438EA Q39004424-0AFFB5B7-6AF6-4BC1-94CE-2476EF77B3D0 Q39013294-12848343-0089-403D-8546-B28236264BE7 Q52365121-3B0219FF-C390-4202-A853-35A36BAEFCCC Q54942652-B843ADD0-8438-47DB-BB3E-0F06B1035FDB Q55458447-F52ECC0D-F878-47E0-9487-327C363B3559

P2860

Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

http://www.wikidata.org/entity/Q33631435

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Nimotuzumab in combination wit ...... single institution experience.

@ast

Nimotuzumab in combination wit ...... single institution experience.

@en

type

label

Nimotuzumab in combination wit ...... single institution experience.

@ast

Nimotuzumab in combination wit ...... single institution experience.

@en

prefLabel

Nimotuzumab in combination wit ...... single institution experience.

@ast

Nimotuzumab in combination wit ...... single institution experience.

@en

P1433

Q33631435-A2C33D05-16A6-4532-9611-4EB10D23B379

P1476

Q33631435-09329CF9-9E76-47F5-8BFD-4F8228EBD136

P2093

Q33631435-0472C8CE-1A6C-4E64-A20F-D60AEED9F857

Q33631435-2E6402E9-D394-4E71-ACFD-14886C089B40

Q33631435-7B738A4F-CA65-4D4A-AFF7-B8063820C317

Q33631435-82D3B90B-6FAE-4C58-A878-88B82AC5F318

Q33631435-946587BA-1975-4807-B36B-77F743967AE9

Q33631435-BD4EE4AC-6DD4-4CBD-A04D-9061CD188CD2

Q33631435-E57A38C3-A2A9-454D-92AD-75CF2DEF4F7B

Q33631435-EF062EE0-7C23-4812-B043-8FB5BA24F789

P2860

Q33631435-1478E921-16CC-42F1-A27A-E699D9015053

Q33631435-21B1B6CB-D8D9-47DE-BCC9-4B13A60EC623

Q33631435-2683466C-8A65-4B51-B199-16B63FCB285B

Q33631435-32EA92C0-08B2-444A-B4D0-10E35D67AC0C

Q33631435-3CC34C9D-5036-44DC-B514-7CF2BC853A81

Q33631435-3F98DDA9-097A-47E3-9E7F-D26922E19593

Q33631435-4B1B1F1D-6B63-4764-9ED7-4E128AED2093

Q33631435-4F3E12ED-8272-47D4-A4C9-0D6D5ACCC715

Q33631435-59BF78D1-F35C-45B5-9C17-B548BC3D6D87

Q33631435-5E220DE4-484C-42F5-BB1C-2EDD1156AFC9

P304

Q33631435-1F0B430A-E0E7-4B2B-B84E-12D3222FE05E

P31

Q33631435-A7922A8A-7496-4CAA-A7D0-94EBB7E0F31C

P356

Q33631435-24C60D7F-3766-4984-A027-1F63CDE827EC

P433

Q33631435-84BD8B93-0316-4794-BEF7-2FB9A52BB2DA

P478

Q33631435-50D6F607-A6C7-470B-9356-C858F1636142

P577

Q33631435-8B49DC41-3856-49DE-BEE9-7AA443796BDD

P5875

Q33631435-29242D00-AC3D-4F9B-B713-5D0F4000F767

P698

Q33631435-D5439FDF-94B4-4D13-A5DF-15011D8587B7

P932

Q33631435-5B585892-4EB4-430E-ABF4-F716A091B81A

P356

P1433

Cancer Biology and Therapy

P1476

Nimotuzumab in combination wit ...... single institution experience.

@en

P2093

Eugenia Jorrín

http://www.w3.org/2001/XMLSchema#string

Ivonne Chon

http://www.w3.org/2001/XMLSchema#string

Jorge Juan Marinello

http://www.w3.org/2001/XMLSchema#string

José Alert

http://www.w3.org/2001/XMLSchema#string

Maria Teresa Solomon

http://www.w3.org/2001/XMLSchema#string

Nederlay Miranda

http://www.w3.org/2001/XMLSchema#string

Patricia Lorenzo-Luaces

http://www.w3.org/2001/XMLSchema#string

Tania Crombet

http://www.w3.org/2001/XMLSchema#string

P2860

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation

Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer

Advances and challenges in the treatment of glioblastoma: a clinician's perspective.

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.

Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.

Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.

Epidermal growth factor receptor targeting in cancer.

Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials.

P304

504-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.28021

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260168300

http://www.w3.org/2001/XMLSchema#string

P698

24521695

http://www.w3.org/2001/XMLSchema#string

P932

4026072

http://www.w3.org/2001/XMLSchema#string